Chen Mei-Ting, Fu Xiao-Hong, Huang He, Wang Zhao, Fang Xiao-Jie, Yao Yu-Yi, Ren Quan-Guang, Chen Ze-Geng, Lin Tong-Yu
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Department of Medical Oncology, Shenzhen Nanshan People's Hospital, Shenzhen, China.
Leuk Lymphoma. 2021 Mar;62(3):571-580. doi: 10.1080/10428194.2020.1839658. Epub 2020 Nov 6.
Our aim was to explore the role of crizotinib, targeted anaplastic lymphoma kinase (ALK), on r/r systemic anaplastic large cell lymphoma (sALCL). The treated group prospectively screened 20 patients. After taking crizotinib in the first week, 16 patients who were tolerant and sensitive received the combination of crizotinib with chemotherapy. The control group included 27 patients receiving chemotherapy in the same hospital during the same period. The objective remission rates of the treated and control group were 81.3% and 74.1% ( = .869), respectively. The progression-free survival rates at two years in treated and control group were 68.7% and 45.0% (HR = 0.42, 95% CI 0.17-0.99, < .05), respectively. The overall survival rates at two years in the treated and control group were 86.1% and 78.9% ( = .385, HR = 0.51, 95% CI 0.11-2.30), respectively. The main adverse events included elevated transaminase, diarrhea, and vision abnormalities. Thus, the combination of crizotinib with chemotherapy might be effective in ALK-positive and crizotinib sensitive r/r sALCL patients.
我们的目的是探讨靶向间变性淋巴瘤激酶（ALK）的克唑替尼在复发/难治性系统性间变性大细胞淋巴瘤（sALCL）中的作用。治疗组前瞻性筛选了20例患者。在第一周服用克唑替尼后，16例耐受且敏感的患者接受了克唑替尼与化疗的联合治疗。对照组包括同期在同一家医院接受化疗的27例患者。治疗组和对照组的客观缓解率分别为81.3%和74.1%（P = 0.869）。治疗组和对照组两年的无进展生存率分别为68.7%和45.0%（HR = 0.42，95%CI 0.17 - 0.99，P < 0.05）。治疗组和对照组两年的总生存率分别为86.1%和78.9%（P = 0.385，HR = 0.51，95%CI 0.11 - 2.30）。主要不良事件包括转氨酶升高、腹泻和视觉异常。因此，克唑替尼与化疗联合使用可能对ALK阳性且对克唑替尼敏感的复发/难治性sALCL患者有效。
